US EditionELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
- On March 15, 2025, AbbVie announced the final analysis of the Phase 3 MIRASOL trial in Seattle, which evaluated ELAHERE versus investigator's choice chemotherapy for folate receptor alpha -positive platinum-resistant ovarian cancer .
- The study was prompted by the need for new therapies for ovarian cancer patients who often present with late-stage disease and develop resistance to platinum-based chemotherapy, leaving them with limited treatment options.
- The MIRASOL trial, with a median follow-up of 30.5 months, enrolled 453 patients with high-grade serous epithelial PROC whose tumors expressed high levels of FRα and who had been treated with up to three prior therapies, stratifying them by prior lines of therapy and IC chemotherapy, with paclitaxel , PLD , and topotecan being the most common IC chemotherapy choices and 14% of patients having one prior line of therapy.
- According to Toon Van Gorp, MD, PhD, Professor of Gynecologic Oncology at the University of Leuven and investigator and presenter, the final data showcase the significant improvement in overall survival benefit of treatment with ELAHERE compared to standard of care chemotherapy, while Svetlana Kobina, MD, PhD, vice president, oncology medical affairs, at AbbVie, stated that the data reinforces the importance of ELAHERE as a transformative therapy for patients with limited options.
- ELAHERE demonstrated a 32% reduction in the risk of death and a 37% reduction in the risk of tumor progression or death compared to IC chemotherapy, with a median overall survival of 16.85 months versus 13.34 months for IC chemotherapy and a higher objective response rate of 41.9% versus 15.9%, along with manageable adverse events, although eye problems, including blurred vision, dry eyes, and sensitivity to light, are common and require monitoring and management.
26 Articles
26 Articles
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
Randomized controlled trials (RCTs) evaluating anti-cancer agents often lack generalizability to real-world oncology patients. Although restrictive eligibility criteria contribute to this issue, the role of selection bias related to prognostic risk remains unclear. In this study, we developed TrialTranslator, a framework designed to systematically evaluate the generalizability of RCTs for oncology therapies. Using a nationwide database of electr…
abc12/WJRT
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC)Data presented in a late-breaking oral presentation at…
Coverage Details
Bias Distribution
- 89% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
